Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Rapid Acting TMS for Suicide Ideation in Depression
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Accelerated Theta Burst Stimulation
- device: Sham Stimulation
Eligibility
Inclusion Criteria:
1. Age 22-65 year old at the time of screening on voluntary or involuntary hold
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Participants will be deemed likely to comply with study protocol and
communicate with study personnel about adverse events and other clinically important
information.
3. Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD
II), according to the criteria defined in the Diagnosis and Statistical Manual of
Mental Disorders, Fifth Edition, Text Revision (DSM-5).
Endorse suicidal ideation (score ≥9 on the SSI-M).
4. Meet the threshold on the MADRS and HAMD-17 with a total score of >/=20 at baseline.
5. Not in a current state of mania (Young Mania Rating Scale) or psychosis (MINI)
6. Have to be TMS naive
7. In good general health, as ascertained by medical history.
8. Scheduled with a psychiatrist
9. Access to clinical rTMS after hospital discharge
10. If participant is of childbearing potential and not already pregnant, must agree to
use adequate contraception prior to study and for the duration of study participation.
11. No recent use (for the actual depressive episode) of rapid acting antidepressive agent
(ketamine)
Exclusion Criteria:
1. Any abnormalities indicated on previous MRI scans e.g. structural neurological
condition, more subcortical lesions than would be expected for age, stroke affecting
stimulated area or connected areas or any other clinically significant abnormality
that might affect safety, study participation, or confound interpretation of study
results.
2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
4. Shrapnel or any ferromagnetic item in the head.
5. Pregnancy: The effects of rTMS on the developing human fetus are incipient and still
uncertain (25). Pregnant women will not be enrolled into this study. Women of
childbearing potential must agree to use adequate contraception (hormonal / barrier
method of birth control or abstinence) prior to study entry and for the duration of
study participation. Females of childbearing-age, will have a pregnancy test prior to
receiving each rTMS stimulation session. Should a woman become pregnant or suspects
she is pregnant while participating in this study, she should inform study staff.
6. Autism Spectrum disorder
7. A diagnosis of obsessive-compulsive disorder (OCD)
8. The presence or diagnosis of prominent anxiety disorder, personality disorder, or
dysthymia
9. Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
10. Active substance use (<1 week) or intoxication verified by toxicology screen--of
cocaine, amphetamines, benzodiazepines
11. Cognitive impairment (including dementia)
12. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
13. Current mania or psychosis
14. Bipolar Affective Disorder I and primary psychotic disorders.
15. Showing symptoms of withdrawal from alcohol or benzodiazepines
16. IQ<70
17. Parkinsonism or other movement d/o determined by PI to interfere with treatment
18. Desirous of getting ECT and previous intolerant exposure to ECT
19. Any other indication the PI feels would comprise data
20. No access to clinical rTMS after discharge.
21. Previous TMS exposure.
22. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO).
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jean-Marie Batail, MD, PhD
650-497-3933
I'm interested
Psoriasis Clinical Trials
Rapid Acting TMS for Suicide Ideation in Depression
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Accelerated Theta Burst Stimulation
- device: Sham Stimulation
Eligibility
Inclusion Criteria:
1. Age 22-65 year old at the time of screening on voluntary or involuntary hold
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Participants will be deemed likely to comply with study protocol and
communicate with study personnel about adverse events and other clinically important
information.
3. Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD
II), according to the criteria defined in the Diagnosis and Statistical Manual of
Mental Disorders, Fifth Edition, Text Revision (DSM-5).
Endorse suicidal ideation (score ≥9 on the SSI-M).
4. Meet the threshold on the MADRS and HAMD-17 with a total score of >/=20 at baseline.
5. Not in a current state of mania (Young Mania Rating Scale) or psychosis (MINI)
6. Have to be TMS naive
7. In good general health, as ascertained by medical history.
8. Scheduled with a psychiatrist
9. Access to clinical rTMS after hospital discharge
10. If participant is of childbearing potential and not already pregnant, must agree to
use adequate contraception prior to study and for the duration of study participation.
11. No recent use (for the actual depressive episode) of rapid acting antidepressive agent
(ketamine)
Exclusion Criteria:
1. Any abnormalities indicated on previous MRI scans e.g. structural neurological
condition, more subcortical lesions than would be expected for age, stroke affecting
stimulated area or connected areas or any other clinically significant abnormality
that might affect safety, study participation, or confound interpretation of study
results.
2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
4. Shrapnel or any ferromagnetic item in the head.
5. Pregnancy: The effects of rTMS on the developing human fetus are incipient and still
uncertain (25). Pregnant women will not be enrolled into this study. Women of
childbearing potential must agree to use adequate contraception (hormonal / barrier
method of birth control or abstinence) prior to study entry and for the duration of
study participation. Females of childbearing-age, will have a pregnancy test prior to
receiving each rTMS stimulation session. Should a woman become pregnant or suspects
she is pregnant while participating in this study, she should inform study staff.
6. Autism Spectrum disorder
7. A diagnosis of obsessive-compulsive disorder (OCD)
8. The presence or diagnosis of prominent anxiety disorder, personality disorder, or
dysthymia
9. Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
10. Active substance use (<1 week) or intoxication verified by toxicology screen--of
cocaine, amphetamines, benzodiazepines
11. Cognitive impairment (including dementia)
12. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
13. Current mania or psychosis
14. Bipolar Affective Disorder I and primary psychotic disorders.
15. Showing symptoms of withdrawal from alcohol or benzodiazepines
16. IQ<70
17. Parkinsonism or other movement d/o determined by PI to interfere with treatment
18. Desirous of getting ECT and previous intolerant exposure to ECT
19. Any other indication the PI feels would comprise data
20. No access to clinical rTMS after discharge.
21. Previous TMS exposure.
22. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO).
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jean-Marie Batail, MD, PhD
650-497-3933
I'm interested
Dermatology Clinical Trials
Rapid Acting TMS for Suicide Ideation in Depression
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Accelerated Theta Burst Stimulation
- device: Sham Stimulation
Eligibility
Inclusion Criteria:
1. Age 22-65 year old at the time of screening on voluntary or involuntary hold
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Participants will be deemed likely to comply with study protocol and
communicate with study personnel about adverse events and other clinically important
information.
3. Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD
II), according to the criteria defined in the Diagnosis and Statistical Manual of
Mental Disorders, Fifth Edition, Text Revision (DSM-5).
Endorse suicidal ideation (score ≥9 on the SSI-M).
4. Meet the threshold on the MADRS and HAMD-17 with a total score of >/=20 at baseline.
5. Not in a current state of mania (Young Mania Rating Scale) or psychosis (MINI)
6. Have to be TMS naive
7. In good general health, as ascertained by medical history.
8. Scheduled with a psychiatrist
9. Access to clinical rTMS after hospital discharge
10. If participant is of childbearing potential and not already pregnant, must agree to
use adequate contraception prior to study and for the duration of study participation.
11. No recent use (for the actual depressive episode) of rapid acting antidepressive agent
(ketamine)
Exclusion Criteria:
1. Any abnormalities indicated on previous MRI scans e.g. structural neurological
condition, more subcortical lesions than would be expected for age, stroke affecting
stimulated area or connected areas or any other clinically significant abnormality
that might affect safety, study participation, or confound interpretation of study
results.
2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
4. Shrapnel or any ferromagnetic item in the head.
5. Pregnancy: The effects of rTMS on the developing human fetus are incipient and still
uncertain (25). Pregnant women will not be enrolled into this study. Women of
childbearing potential must agree to use adequate contraception (hormonal / barrier
method of birth control or abstinence) prior to study entry and for the duration of
study participation. Females of childbearing-age, will have a pregnancy test prior to
receiving each rTMS stimulation session. Should a woman become pregnant or suspects
she is pregnant while participating in this study, she should inform study staff.
6. Autism Spectrum disorder
7. A diagnosis of obsessive-compulsive disorder (OCD)
8. The presence or diagnosis of prominent anxiety disorder, personality disorder, or
dysthymia
9. Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
10. Active substance use (<1 week) or intoxication verified by toxicology screen--of
cocaine, amphetamines, benzodiazepines
11. Cognitive impairment (including dementia)
12. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
13. Current mania or psychosis
14. Bipolar Affective Disorder I and primary psychotic disorders.
15. Showing symptoms of withdrawal from alcohol or benzodiazepines
16. IQ<70
17. Parkinsonism or other movement d/o determined by PI to interfere with treatment
18. Desirous of getting ECT and previous intolerant exposure to ECT
19. Any other indication the PI feels would comprise data
20. No access to clinical rTMS after discharge.
21. Previous TMS exposure.
22. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO).
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jean-Marie Batail, MD, PhD
650-497-3933
I'm interested
Pediatric Dermatology Clinical Trials
Rapid Acting TMS for Suicide Ideation in Depression
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Accelerated Theta Burst Stimulation
- device: Sham Stimulation
Eligibility
Inclusion Criteria:
1. Age 22-65 year old at the time of screening on voluntary or involuntary hold
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Participants will be deemed likely to comply with study protocol and
communicate with study personnel about adverse events and other clinically important
information.
3. Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD
II), according to the criteria defined in the Diagnosis and Statistical Manual of
Mental Disorders, Fifth Edition, Text Revision (DSM-5).
Endorse suicidal ideation (score ≥9 on the SSI-M).
4. Meet the threshold on the MADRS and HAMD-17 with a total score of >/=20 at baseline.
5. Not in a current state of mania (Young Mania Rating Scale) or psychosis (MINI)
6. Have to be TMS naive
7. In good general health, as ascertained by medical history.
8. Scheduled with a psychiatrist
9. Access to clinical rTMS after hospital discharge
10. If participant is of childbearing potential and not already pregnant, must agree to
use adequate contraception prior to study and for the duration of study participation.
11. No recent use (for the actual depressive episode) of rapid acting antidepressive agent
(ketamine)
Exclusion Criteria:
1. Any abnormalities indicated on previous MRI scans e.g. structural neurological
condition, more subcortical lesions than would be expected for age, stroke affecting
stimulated area or connected areas or any other clinically significant abnormality
that might affect safety, study participation, or confound interpretation of study
results.
2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
4. Shrapnel or any ferromagnetic item in the head.
5. Pregnancy: The effects of rTMS on the developing human fetus are incipient and still
uncertain (25). Pregnant women will not be enrolled into this study. Women of
childbearing potential must agree to use adequate contraception (hormonal / barrier
method of birth control or abstinence) prior to study entry and for the duration of
study participation. Females of childbearing-age, will have a pregnancy test prior to
receiving each rTMS stimulation session. Should a woman become pregnant or suspects
she is pregnant while participating in this study, she should inform study staff.
6. Autism Spectrum disorder
7. A diagnosis of obsessive-compulsive disorder (OCD)
8. The presence or diagnosis of prominent anxiety disorder, personality disorder, or
dysthymia
9. Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
10. Active substance use (<1 week) or intoxication verified by toxicology screen--of
cocaine, amphetamines, benzodiazepines
11. Cognitive impairment (including dementia)
12. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
13. Current mania or psychosis
14. Bipolar Affective Disorder I and primary psychotic disorders.
15. Showing symptoms of withdrawal from alcohol or benzodiazepines
16. IQ<70
17. Parkinsonism or other movement d/o determined by PI to interfere with treatment
18. Desirous of getting ECT and previous intolerant exposure to ECT
19. Any other indication the PI feels would comprise data
20. No access to clinical rTMS after discharge.
21. Previous TMS exposure.
22. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO).
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jean-Marie Batail, MD, PhD
650-497-3933
I'm interested
Rapid Acting TMS for Suicide Ideation in Depression
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Accelerated Theta Burst Stimulation
- device: Sham Stimulation
Eligibility
Inclusion Criteria:
1. Age 22-65 year old at the time of screening on voluntary or involuntary hold
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Participants will be deemed likely to comply with study protocol and
communicate with study personnel about adverse events and other clinically important
information.
3. Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD
II), according to the criteria defined in the Diagnosis and Statistical Manual of
Mental Disorders, Fifth Edition, Text Revision (DSM-5).
Endorse suicidal ideation (score ≥9 on the SSI-M).
4. Meet the threshold on the MADRS and HAMD-17 with a total score of >/=20 at baseline.
5. Not in a current state of mania (Young Mania Rating Scale) or psychosis (MINI)
6. Have to be TMS naive
7. In good general health, as ascertained by medical history.
8. Scheduled with a psychiatrist
9. Access to clinical rTMS after hospital discharge
10. If participant is of childbearing potential and not already pregnant, must agree to
use adequate contraception prior to study and for the duration of study participation.
11. No recent use (for the actual depressive episode) of rapid acting antidepressive agent
(ketamine)
Exclusion Criteria:
1. Any abnormalities indicated on previous MRI scans e.g. structural neurological
condition, more subcortical lesions than would be expected for age, stroke affecting
stimulated area or connected areas or any other clinically significant abnormality
that might affect safety, study participation, or confound interpretation of study
results.
2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
4. Shrapnel or any ferromagnetic item in the head.
5. Pregnancy: The effects of rTMS on the developing human fetus are incipient and still
uncertain (25). Pregnant women will not be enrolled into this study. Women of
childbearing potential must agree to use adequate contraception (hormonal / barrier
method of birth control or abstinence) prior to study entry and for the duration of
study participation. Females of childbearing-age, will have a pregnancy test prior to
receiving each rTMS stimulation session. Should a woman become pregnant or suspects
she is pregnant while participating in this study, she should inform study staff.
6. Autism Spectrum disorder
7. A diagnosis of obsessive-compulsive disorder (OCD)
8. The presence or diagnosis of prominent anxiety disorder, personality disorder, or
dysthymia
9. Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
10. Active substance use (<1 week) or intoxication verified by toxicology screen--of
cocaine, amphetamines, benzodiazepines
11. Cognitive impairment (including dementia)
12. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
13. Current mania or psychosis
14. Bipolar Affective Disorder I and primary psychotic disorders.
15. Showing symptoms of withdrawal from alcohol or benzodiazepines
16. IQ<70
17. Parkinsonism or other movement d/o determined by PI to interfere with treatment
18. Desirous of getting ECT and previous intolerant exposure to ECT
19. Any other indication the PI feels would comprise data
20. No access to clinical rTMS after discharge.
21. Previous TMS exposure.
22. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO).
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jean-Marie Batail, MD, PhD
650-497-3933
I'm interested
Rapid Acting TMS for Suicide Ideation in Depression
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Accelerated Theta Burst Stimulation
- device: Sham Stimulation
Eligibility
Inclusion Criteria:
1. Age 22-65 year old at the time of screening on voluntary or involuntary hold
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Participants will be deemed likely to comply with study protocol and
communicate with study personnel about adverse events and other clinically important
information.
3. Diagnosed with Major Depressive Disorder (MDD) or Bipolar Affective Disorder II (BAPD
II), according to the criteria defined in the Diagnosis and Statistical Manual of
Mental Disorders, Fifth Edition, Text Revision (DSM-5).
Endorse suicidal ideation (score ≥9 on the SSI-M).
4. Meet the threshold on the MADRS and HAMD-17 with a total score of >/=20 at baseline.
5. Not in a current state of mania (Young Mania Rating Scale) or psychosis (MINI)
6. Have to be TMS naive
7. In good general health, as ascertained by medical history.
8. Scheduled with a psychiatrist
9. Access to clinical rTMS after hospital discharge
10. If participant is of childbearing potential and not already pregnant, must agree to
use adequate contraception prior to study and for the duration of study participation.
11. No recent use (for the actual depressive episode) of rapid acting antidepressive agent
(ketamine)
Exclusion Criteria:
1. Any abnormalities indicated on previous MRI scans e.g. structural neurological
condition, more subcortical lesions than would be expected for age, stroke affecting
stimulated area or connected areas or any other clinically significant abnormality
that might affect safety, study participation, or confound interpretation of study
results.
2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
4. Shrapnel or any ferromagnetic item in the head.
5. Pregnancy: The effects of rTMS on the developing human fetus are incipient and still
uncertain (25). Pregnant women will not be enrolled into this study. Women of
childbearing potential must agree to use adequate contraception (hormonal / barrier
method of birth control or abstinence) prior to study entry and for the duration of
study participation. Females of childbearing-age, will have a pregnancy test prior to
receiving each rTMS stimulation session. Should a woman become pregnant or suspects
she is pregnant while participating in this study, she should inform study staff.
6. Autism Spectrum disorder
7. A diagnosis of obsessive-compulsive disorder (OCD)
8. The presence or diagnosis of prominent anxiety disorder, personality disorder, or
dysthymia
9. Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
10. Active substance use (<1 week) or intoxication verified by toxicology screen--of
cocaine, amphetamines, benzodiazepines
11. Cognitive impairment (including dementia)
12. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
13. Current mania or psychosis
14. Bipolar Affective Disorder I and primary psychotic disorders.
15. Showing symptoms of withdrawal from alcohol or benzodiazepines
16. IQ<70
17. Parkinsonism or other movement d/o determined by PI to interfere with treatment
18. Desirous of getting ECT and previous intolerant exposure to ECT
19. Any other indication the PI feels would comprise data
20. No access to clinical rTMS after discharge.
21. Previous TMS exposure.
22. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO).
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jean-Marie Batail, MD, PhD
650-497-3933
I'm interested